Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 2.0 | 4.0 |
Min SIP Amount | ₹200 | ₹100 |
Expense Ratio | 2.45 | 1.87 |
NAV | ₹29.76 | ₹40.60 |
Fund Started | 08 Feb 2019 | 25 Jun 2018 |
Fund Size | ₹88.29 Cr | ₹6161.81 Cr |
Exit Load | Exit Load for units in excess of 12% of the investment,1% will be charged for redemption within 90 days. | Exit load of 1% if redeemed within 15 days. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | -0.40% | 3.41% |
3 Year | 20.22% | 28.37% |
5 Year | 14.96% | 21.82% |
1 Year
3 Year
5 Year
Equity | 94.33% | 95.88% |
Cash | 5.65% | 4.12% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 9.72% |
Apollo Hospitals Enterprise Ltd. | 5.79% |
Cipla Ltd. | 5.62% |
Torrent Pharmaceuticals Ltd. | 5.29% |
Fortis Healthcare Ltd. | 4.35% |
Divi's Laboratories Ltd. | 4.28% |
Piramal Pharma Ltd. | 4.12% |
Alkem Laboratories Ltd. | 3.73% |
Neuland Laboratories Ltd. | 3.68% |
Aurobindo Pharma Ltd. | 3.64% |
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 11.71% |
Dr. Reddy's Laboratories Ltd. | 9.47% |
Divi's Laboratories Ltd. | 9.23% |
Cipla Ltd. | 7.39% |
Aurobindo Pharma Ltd. | 6.53% |
Lupin Ltd. | 5.44% |
Alkem Laboratories Ltd. | 4.00% |
Mankind Pharma Ltd. | 3.50% |
Biocon Ltd. | 3.21% |
Gland Pharma Ltd. | 2.88% |
Name | Karan Doshi | Dharmesh Kakkad |
Start Date | 31 Jul 2023 | 23 Feb 2021 |
Name
Start Date
Description | The Scheme seeks to achieve long term capital appreciation by predominantly investing in equity and equity related instruments of companies engaged in Healthcare and Allied sectors. | The scheme seeks to generate long-term capital appreciation by creating a portfolio that is invested in equity and equity related securities of pharma, healthcare, hospitals, diagnostics, wellness and allied companies. |
Launch Date | 08 Feb 2019 | 25 Jun 2018 |
Description
Launch Date